In vitro activities of small peptides from snake venom against clinical isolates of drug-resistant Mycobacterium tuberculosis

Int J Antimicrob Agents. 2003 Aug;22(2):172-4. doi: 10.1016/s0924-8579(03)00110-9.

Abstract

The recent re-emergence of tuberculosis, especially the multidrug-resistant cases, has highlighted the importance of screening effective novel drugs against Mycobacterium tuberculosis. In this study, the in vitro activities of small peptides isolated from snake venom were investigated against multidrug-resistant M. tuberculosis. Minimum inhibitory concentrations (MICs) were determined by the Bactec TB-460 radiometric method. A small peptide with the amino acid sequence ECYRKSDIVTCEPWQKFCYREVTFFPNHPVYLSGCASECTETNSKWCCTTDKCNRARGG (designated as vgf-1) from Naja atra (isolated from Yunnan province of China) venom had in vitro activity against clinically isolated multidrug-resistant strains of M. tuberculosis. The MIC was 8.5 mg/l. The antimycobacterial domain of this 60aa peptide is under investigation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antitubercular Agents / chemistry
  • Antitubercular Agents / isolation & purification
  • Antitubercular Agents / pharmacology*
  • Drug Resistance, Multiple, Bacterial
  • Elapidae / genetics
  • Elapidae / metabolism
  • Humans
  • In Vitro Techniques
  • Molecular Sequence Data
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / isolation & purification
  • Peptides / chemistry
  • Peptides / genetics
  • Peptides / isolation & purification
  • Peptides / pharmacology*
  • Snake Venoms / chemistry*
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / microbiology

Substances

  • Antitubercular Agents
  • Peptides
  • Snake Venoms